Poster No:
616
Submission Type:
Abstract Submission
Authors:
Sunah Choi1, Minah Kim2, Sang Soo Cho1, Woori Choi1, Harin Oh1, Jongrak Kim1, Jungha Lee1, Su-Jin An1, Jun Seo Hwang1, Yun-Sang Lee3, In Chan Song4, Sun-Young Moon5, Silvia Kyungjin Lho6, Jun Soo Kwon1
Institutions:
1Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences, Seoul, Seoul, 2Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Seoul, 3Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Seoul, 4Department of Radiology, Seoul National University College of Medicine, Seoul, Seoul, 5Department of Public Health Medical Services, Seoul National University Bundang Hospital, Seoul, Seoul, 6Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Seoul
First Author:
Sunah Choi
Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences
Seoul, Seoul
Co-Author(s):
Minah Kim
Department of Neuropsychiatry, Seoul National University Hospital
Seoul, Seoul
Sang Soo Cho
Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences
Seoul, Seoul
Woori Choi
Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences
Seoul, Seoul
Harin Oh
Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences
Seoul, Seoul
Jongrak Kim
Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences
Seoul, Seoul
Jungha Lee
Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences
Seoul, Seoul
Su-Jin An
Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences
Seoul, Seoul
Jun Seo Hwang
Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences
Seoul, Seoul
Yun-Sang Lee
Department of Nuclear Medicine, Seoul National University College of Medicine
Seoul, Seoul
In Chan Song
Department of Radiology, Seoul National University College of Medicine
Seoul, Seoul
Sun-Young Moon
Department of Public Health Medical Services, Seoul National University Bundang Hospital
Seoul, Seoul
Silvia Kyungjin Lho
Seoul Metropolitan Government-Seoul National University Boramae Medical Center
Seoul, Seoul
Jun Soo Kwon
Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences
Seoul, Seoul
Introduction:
The underlying mechanism of negative and cognitive symptoms remains poorly understood in schizophrenia. Studies suggested alterations in the medial orbitofrontal cortex (mOFC) and abnormal astrocytes in the etiology of the symptoms (Schobel et al. 2009; Meyer et al. 2011; Shukla et al. 2019). However, there is inconsistency in in vivo results using previous imaging targets (Meyer et al. 2020). Reactive astrocytes increase monoamine oxidase B (MAO-B) expression, and MAO-B binding positron emission tomography (PET) enables the in vivo imaging of astrocyte reactivity (Ng et al. 2017; Nisha Aji et al. 2023). We aimed to investigate the association between negative and cognitive symptoms and reactive astrocytes in the mOFC in schizophrenia patients using MAO-B binding PET.
Methods:
We analyzed MAO-B binding [18F]THK5351 PET data from 33 schizophrenia patients and 35 age- and sex-matched healthy controls. We examined group differences in standardized uptake value ratio (SUVr) in the mOFC and their correlation with Positive and Negative Syndrome Scale (PANSS) negative symptom scores and Wisconsin Card Sorting Test (WCST) performance scores.
Results:
We found higher SUVr in the bilateral mOFC in schizophrenia patients compared to healthy controls (left, t = -2.01, p = 0.048; right, t = -2.04, p = 0.045). There were negative correlations between SUVr and WCST scores (left, r = -0.33, p = 0.006; right, r = -0.26, p = 0.032). The correlation between SUVr and PANSS negative symptom scores was not significant.
Conclusions:
Our findings support an association between reactive astrocytes in the mOFC and cognitive functioning including executive function in schizophrenia. This study suggests a potential biomarker for the neurobiological mechanism of cognitive symptoms in schizophrenia.
Disorders of the Nervous System:
Psychiatric (eg. Depression, Anxiety, Schizophrenia) 1
Higher Cognitive Functions:
Executive Function, Cognitive Control and Decision Making
Modeling and Analysis Methods:
PET Modeling and Analysis 2
Keywords:
Astrocyte
Cognition
Cortex
Positron Emission Tomography (PET)
Schizophrenia
1|2Indicates the priority used for review
Provide references using author date format
[1] Meyer JH, Cervenka S, Kim M-J, et al (2020) Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. The Lancet Psychiatry 7:1064–1074
[2] Meyer U, Schwarz MJ, Müller N (2011) Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther 132:96–110
[3] Ng KP, Pascoal TA, Mathotaarachchi S, et al (2017) Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res Ther 9:1–9
[4] Nisha Aji K, Meyer JH, Rusjan PM, Mizrahi R (2023) Monoamine Oxidase B (MAO-B): A Target for Rational Drug Development in Schizophrenia Using PET Imaging as an Example. In: Drug Development in Psychiatry. Springer, pp 335–362
[5] Schobel SA, Kelly MA, Corcoran CM, et al (2009) Anterior hippocampal and orbitofrontal cortical structural brain abnormalities in association with cognitive deficits in schizophrenia. Schizophr Res 114:110–118
[6] Shukla DK, Chiappelli JJ, Sampath H, et al (2019) Aberrant frontostriatal connectivity in negative symptoms of schizophrenia. Schizophr Bull 45:1051–1059